Published on 3 Aug 2022 on Zacks via Yahoo Finance
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 8.77%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.50 per share when it actually produced a loss of $0.52, delivering a surprise of -4%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.